

01 MAY 2006

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		Attorney Docket No. 0508-1160 U.S. Application No. 10/577658
INTERNATIONAL APPLN. NO. PCT/FR2004/002797	INTERNATIONAL FILING DATE October 29, 2004	PRIORITY DATE CLAIMED October 30, 2003
TITLE OF INVENTION: NOVEL PHOSPHATE-BINDING PROTEIN, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF		
APPLICANT(S) FOR DO/EO/US: Eric CHABRIERE; Carlos CONTRERAS-MARTEL; Juan FONTECILLA-CAMPS		
Applicant herewith submits to the United States Designated Elected Office (DO/EO/US) the following items and other information: <ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.4. <input checked="" type="checkbox"/> The US has been elected (Article 31).5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c)(2))<ol style="list-style-type: none">a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> has been communicated by the International Bureau. See attached PCT/IB/308.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2))<ol style="list-style-type: none">a. <input checked="" type="checkbox"/> is attached hereto.b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))<ol style="list-style-type: none">a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> have been communicated by the International Bureau.c. <input type="checkbox"/> have not been made, however, the time limit for making such amendments has NOT expired.d. <input type="checkbox"/> have not been made and will not be made.8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4))10. <input type="checkbox"/> A Declaration of Inventorship for purposes of U.S.A. designation pursuant to rule 4.17(iv).))11. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 12 to 23 below concern document(s) or information included:</p> <ol style="list-style-type: none">12. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS) w/PTO-1449 - <input checked="" type="checkbox"/> Copy of IDS citations. - <input checked="" type="checkbox"/> PCT/ISA/210 International Search Report included13. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)).14. <input checked="" type="checkbox"/> A preliminary amendment.15. <input checked="" type="checkbox"/> An Application Data Sheet under 37 C.F.R. 1.76.16. <input checked="" type="checkbox"/> Itemized Return Receipt Postcard17. <input checked="" type="checkbox"/> Abstract18. <input type="checkbox"/> A substitute specification.19. <input type="checkbox"/> Power of Attorney and Statement under 37 CFR §3.73(b)<ol style="list-style-type: none">a. <input type="checkbox"/> Newly executed Power of Attorneyb. <input type="checkbox"/> A change of Power of Attorney and/or change of address letter.20. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.21. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).22. <input type="checkbox"/> A second copy of the English language translation of the international application (35 U.S.C. 154(d)(4)).23. <input checked="" type="checkbox"/> Other items or information: SUBMISSION UNDER 37 C.F.R. §1.821 FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES (PAPER SEQUENCE LISTING)		

U.S. APPLICATION NO. 10/577658		INTERNATIONAL APPLN. NO. PCT/FR2004/002797		ATTORNEY DOCKET NO. 0508-1160	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. <input checked="" type="checkbox"/> The following fees are submitted: <p style="text-align: center;">PCT FEES - NATIONAL STAGE</p>				CALCULATIONS PTO USE ONLY	
<u>Fee Description</u>					
Basic National Stage Fee				\$300.00	
Non ISA/US Search Provided National Stage Search Fee				\$400.00	
<input type="checkbox"/> US was the IPEA And all claims satisfied the provisions of PCT Article 33 (1)-(4) National Stage Examination Fee				\$200.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20- <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (Fee Code 1617/2617)				\$130.00	
National Stage Application size fee each additional 50 sheets in excess of 100 Fee Code 1681/2681		Additional Sheets - 100 = = X <div style="text-align: center;">50</div>		Fee From Below \$125.00 \$0.00	
CLAIMS		NUMBER FILED	NUMBER EXTRA	RATE	
Independent Claims Fee Codes 1614 / 2614		2 - 3 =	0	x \$100.00	\$0.00
Total Claims Fee Codes 1615 / 2615		17 - 20 =	0	x \$25.00	\$0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable) Fee Code 1616 / 2616				+ \$360.00	\$0.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). Fee Code 1618					\$0.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). (Fee code 8021) <div style="text-align: right;">\$40.00 per property +</div>				\$0.00	
TOTAL FEES ENCLOSED =				\$1,030.00	
				Amount to be refunded:	\$
				Charged:	\$
<input checked="" type="checkbox"/> A check in the amount of \$1,030.00 to cover the above fees is attached. <input type="checkbox"/> The Director is hereby authorized to charge indicated fees and credit any overpayment to Deposit Account No. 25-0120 in the name of Young & Thompson. A duplicate copy of this sheet is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17.					
SEND ALL CORRESPONDENCE TO: YOUNG & THOMPSON 745 South 23 rd Street Arlington, VA 22202 Telephone: (703) 521-2297 Facsimile: (703) 685-0573			<div style="font-family: cursive; font-size: 1.2em; margin-bottom: 5px;">Benoit Castel</div> SIGNATURE		
Y&T Customer No. 00466 BC/mps			Benoit Castel, Reg. No. 35,041 NAME, REGISTRATION NUMBER		
			May 1, 2006 DATE		

40/577658
MAY 01 2006

Mail Stop Sequence
PATENT
0508-1160

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re application of

Eric CHABRIERE et al.

Conf.

Application No. NEW NATIONAL PHASE Group

Filed May 1, 2006

Examiner

NOVEL PHOSPHATE-BINDING PROTEIN, PHARMACEUTICAL COMPOSTIOIONS
CONTAINING SAME AND USE THEREOF

**SUBMISSION UNDER 37 C.F.R. §1.821
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


May 1, 2006

Sir:

Applicant(s) attach(es) to the present paper a
"Sequence Listing", as required by Rule 821(c).

Respectfully submitted,

YOUNG & THOMPSON



Benoit Castel, Reg. No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573
(703) 979-4709

BC/mps